Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Haemonetics
HAE
$3.97B
| $299M | 0.26% |
2,484,400
+108,700
| +5% | +$10.7M |
|
|
K
77
DELISTED
Kellanova
K
| $296M | 0.26% |
5,883,042
+664,241
| +13% | +$35.3M |
|
78
WEC Energy
WEC
$34.8B
| $288M | 0.25% |
3,455,802
-637,500
| -16% | -$51.1M |
|
79
Philip Morris
PM
$290B
| $288M | 0.25% |
3,663,243
+1,470,000
| +67% | +$121M |
|
80
Exelixis
EXEL
$12.7B
| $288M | 0.25% |
13,454,473
+3,889,200
| +41% | +$81.5M |
|
81
Ventas
VTR
$44.6B
| $287M | 0.25% |
4,199,622
+938,202
| +29% | +$59.8M |
|
82
General Mills
GIS
$20.2B
| $279M | 0.25% |
5,313,884
+1,639,900
| +45% | +$84.7M |
|
|
MBT
83
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
| $277M | 0.24% |
29,739,946
+2,086,350
| +8% | +$17M |
|
84
Fortinet
FTNT
$119B
| $272M | 0.24% |
17,725,000
-968,500
| -5% | -$15.9M |
|
85
Target
TGT
$69.2B
| $271M | 0.24% |
3,129,200
+2,690,600
| +613% | +$217M |
|
86
Kinder Morgan
KMI
$70.1B
| $268M | 0.24% |
12,845,700
-45,400
| -0.4% | -$915K |
|
87
Edison International
EIX
$26.9B
| $267M | 0.24% |
3,963,890
-6,700
| -0.2% | -$416K |
|
88
Zoetis
ZTS
$31.1B
| $267M | 0.24% |
2,351,975
-237,400
| -9% | -$24.9M |
|
89
Pinnacle West Capital
PNW
$12.1B
| $264M | 0.23% |
2,804,750
+109,400
| +4% | +$10.4M |
|
90
GoDaddy
GDDY
$11.5B
| $257M | 0.23% |
3,660,300
+94,900
| +3% | +$7.16M |
|
91
Essex Property Trust
ESS
$18.2B
| $256M | 0.23% |
878,226
+86,426
| +11% | +$24.9M |
|
|
TWTR
92
DELISTED
Twitter, Inc.
TWTR
| $256M | 0.23% |
7,337,600
+5,636,902
| +331% | +$207M |
|
93
Eli Lilly
LLY
$1.08T
| $256M | 0.23% |
2,308,601
+1,583,947
| +219% | +$187M |
|
94
Clorox
CLX
$13.1B
| $250M | 0.22% |
1,634,794
-587,200
| -26% | -$89.7M |
|
|
RHT
95
DELISTED
Red Hat Inc
RHT
| $248M | 0.22% |
1,320,765
+1,198,200
| +978% | +$221M |
|
96
Idexx Laboratories
IDXX
$46.2B
| $246M | 0.22% |
893,025
-196,100
| -18% | -$48.3M |
|
|
CHL
97
DELISTED
China Mobile Limited
CHL
| $245M | 0.22% |
5,420,097
+190,000
| +4% | +$8.84M |
|
98
Teradyne
TER
$59.3B
| $244M | 0.21% |
5,084,800
+985,600
| +24% | +$44.7M |
|
99
MSCI
MSCI
$40.8B
| $238M | 0.21% |
998,767
+52,400
| +6% | +$11.7M |
|
100
United Therapeutics
UTHR
$22.1B
| $237M | 0.21% |
3,040,978
+799,200
| +36% | +$74.7M |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.